Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.26 | N/A | +1.38% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.26 | N/A | +1.38% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in the company's core products and future growth. They noted the importance of their pipeline but did not provide specific guidance.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
AbbVie's earnings report shows a positive surprise on EPS, indicating better-than-expected profitability. The stock reacted positively, rising 1.65%, likely driven by management's confidence in their core products and pipeline. However, the lack of revenue data and guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO SANTANDER SA ADR
Jul 23, 2019